Meningiomas are usually benign solitary intracranial tumors. In rare cases, atypical [World Health Organization (WHO) grade II) and anaplastic (WHO grade III) meningiomas can lead to distant metastases. Meningioma cells express somatostatin receptor subtype 2, providing a rationale for peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs in patients with aggressive meningiomas. A 68-year-old woman treated surgically in 2013 for a grade II cerebral meningioma presented 6 years later with pulmonary relapse. Complete response was achieved after 4 cycles of 177 Lu-DOTATATE PRRT, without recurrence after 3 years of follow-up.
Gillon et al. (Thu,) studied this question.